<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17951898</article-id><article-id pub-id-type="pmc">2635976</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2007_55_6_427_36476</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Pegaptanib sodium for ocular vascular disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shukla</surname><given-names>Dhananjay</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Namperumalsamy</surname><given-names>Perumalsamy</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Goldbaum</surname><given-names>Mauro</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cunningham Jr</surname><given-names>Emmett T</given-names></name><degrees>MD, PhD, MPH</degrees></contrib><aff>Retina-Vitreous Service, Aravind Eye Hospital and Postgraduate Institute, Anna Nagar, Madurai, (DS); Chairman, Aravind Eye Care System, Anna Nagar,  Madurai, India (PN); OSI Eyetech, Inc., New York, USA (MG); and Director, The Uveitis Service, California Pacific Medical Center, San Francisco, California and Adjunct Clinical Professor, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA (ETC)</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Dr. Cunningham Emmett T Jr, 801 Gateway Boulevard, Suite 410, South San Francisco, California 94080, USA. Email:<email>emmett_cunningham@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2007</year></pub-date><volume>55</volume><issue>6</issue><fpage>427</fpage><lpage>430</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Pegaptanib sodium (Macugen<sup>TM</sup>) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF)<sub> 165</sub> , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF<sub> 121</sub> . After more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety profile has also been confirmed in patients receiving up to three years of therapy. Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the first available aptamer approved for therapeutic use in humans and the first VEGF inhibitor available for the treatment of ocular vascular diseases.</p></abstract><kwd-group><kwd>Age-related macular degeneration</kwd><kwd>aptamer</kwd><kwd>diabetic macular edema</kwd><kwd>pegaptanib</kwd><kwd>vascular endothelial growth factor</kwd></kwd-group></article-meta></front><body><p>Studies of the pathophysiology of neovascular diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), have demonstrated a central role for vascular endothelial growth factor (VEGF; also known as VEGF-A) in the pathogenesis of these disorders. VEGF acts as a master regulator and promoter of angiogenesis<xref ref-type="bibr" rid="ref1">1</xref>  and is also the most potent known promoter of vascular permeability.<xref ref-type="bibr" rid="ref2">2</xref>  Ocular VEGF concentrations were found to be elevated in the eyes of patients suffering from neovascularizing conditions and preclinical studies showed that VEGF was both necessary and sufficient for the development of ocular neovascularization.<xref ref-type="bibr" rid="ref3">3</xref> </p><p>These studies provided compelling evidence for the use of VEGF inhibitors in treating AMD patients. To date, two VEGF-targeting therapies have received regulatory approval for the treatment of neovascular AMD - pegaptanib sodium (Macugen<sup> TM</sup> ; OSI-Eyetech, Inc. and Pfizer, Inc.) approved in December 2004 and ranibizumab (Lucentis<sup> TM</sup> ; Genentech, Inc.) approved in June 2006. Pegaptanib is an RNA aptamer that inhibits the VEGF<sub> 165</sub>  isoform while sparing VEGF<sub> 121</sub> . In contrast, ranibizumab is a Fab antibody fragment that binds to and inhibits all VEGF isoforms.<xref ref-type="bibr" rid="ref4">4</xref>  This review focuses entirely on pegaptanib (for more detailed reviews see Ng <italic> et al</italic> .<xref ref-type="bibr" rid="ref3">3</xref> ; Cunningham <italic> et al.</italic><xref ref-type="bibr" rid="ref5">5</xref> ).</p><sec sec-type=""><title>Development of Pegaptanib</title><p>Pegaptanib was developed in the 1990s using the SELEX (selective evolution of ligands by exponential enrichment) technique. The result was a 29-nucleotide aptamer, with a chemically modified RNA backbone that increases nuclease resistance and a 5&#x02032; terminus that includes a 40kD polyethylene glycol moiety for prolonged tissue residence <xref ref-type="fig" rid="F1">[Fig. 1]</xref>.<xref ref-type="bibr" rid="ref3">3</xref>  Pegaptanib was shown to bind VEGF<sub> 165</sub>  with high specificity (kD = 200 pM) and inhibited VEGF<sub> 165</sub> -induced responses, including cell proliferation <italic> in vitro</italic>  and vascular permeability <italic> in vivo</italic> , while not affecting responses to VEGF<sub> 121</sub> . Pegaptanib proved to be stable in human plasma for more than 18h, while in monkeys pegaptanib administered into the vitreous was detectable in the vitreous for four weeks after a single dose.<xref ref-type="bibr" rid="ref3">3</xref></p></sec><sec sec-type=""><title>Preclinical Findings</title><p>In rodent models,VEGF<sub> 164</sub>  (the rodent equivalent of human VEGF<sub> 165</sub> ) acts as a potent inflammatory cytokine, mediating both ischemia-induced neovascularization and diabetes-induced breakdown of the blood-retinal barrier (BRB). In these experiments, intravitreous pegaptanib was shown to significantly reduce pathological neovascularization, while leaving physiological vascularization unimpaired<xref ref-type="bibr" rid="ref6">6</xref>  and was also able to reverse diabetes-induced BRB breakdown.<xref ref-type="bibr" rid="ref7">7</xref>  Moreover, VEGF<sub> 165</sub>  proved to be dispensable for mediating VEGF&#x02032;s role in protecting retinal neurons from ischemia-induced apoptosis.<xref ref-type="bibr" rid="ref8">8</xref>  These data suggested that intravitreous pegaptanib could provide a safe and effective treatment against both ocular neovascularization and diabetes-induced retinal vascular damage.</p></sec><sec sec-type=""><title>Clinical Studies</title><sec><title>Neovascular AMD</title><p>Pivotal clinical trial data have demonstrated that pegaptanib is both effective and safe for the treatment of neovascular AMD. These data were derived from two randomized, double-masked studies known jointly as the V.I.S.I.O.N. (VEGF Inhibition Study in Ocular Neovascularization) trials.<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>  A total of 1186 subjects with any angiographic subtypes of neovascular AMD were included. Patients received intravitreous injections of 0.3 mg, 1 mg or 3 mg pegaptanib or sham injections every six weeks for 48 weeks. Subjects with predominantly classic lesions could also have received photodynamic therapy with verteporfin (PDT; Visudyne<sup> TM</sup> , Novartis) at investigator discretion. After one year, the 0.3 mg dose conferred a significant clinical benefit compared to sham treatment as measured by proportions of patients losing &#x0003c; 15 letters of visual acuity (VA); compared with 55% (164/296) of patients receiving sham injections, 70% (206/294) of patients receiving 0.3 mg of pegaptanib met this primary endpoint (<italic> P </italic> &#x0003c; 0.001). In contrast to PDT, clinical benefit was seen irrespective of angiographic AMD subtype, baseline vision or lesion size and led to the clinical approval of pegaptanib for the treatment of all angiographic subtypes of neovascular AMD. The 1 mg and 3 mg doses showed no additional benefit beyond the 0.3 mg dose.<xref ref-type="bibr" rid="ref9">9</xref>  Treatment with 0.3 mg pegaptanib was also efficacious as determined by mean VA change, proportions of patients gaining vision and likelihood of severe vision loss. In an extension of the V.I.S.I.O.N. study, patients in the pegaptanib arms were rerandomized to continue or discontinue therapy for 48 more weeks.<xref ref-type="bibr" rid="ref10">10</xref>  Compared to patients discontinuing pegaptanib or receiving usual care, those remaining on 0.3 mg pegaptanib received additional significant clinical benefit in the second year. Further subgroup analyses suggested that pegaptanib treatment was especially effective in those patients who were treated early in the course of their disease.<xref ref-type="bibr" rid="ref11">11</xref> </p><p>Pegaptanib showed an excellent safety profile. All dosages were safe, with most adverse events attributable to the injection procedure rather than to the study drug itself. In the first year, serious adverse events occurred with &#x0003c; 1% of intravitreous injections<xref ref-type="bibr" rid="ref9">9</xref>  and no new safety signals have been identified in patients receiving pegaptanib for two and three years.<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref>  The frequencies of serious ocular adverse events for all three years are presented in <xref ref-type="table" rid="T1">Table 1</xref>.<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref> In addition, no systemic safety signals have emerged over this period. These conclusions have also been confirmed in assessments of systemic parameters following intravitreous injection of 1 mg and 3 mg pegaptanib.<xref ref-type="bibr" rid="ref14">14</xref> </p></sec><sec><title>Diabetic macular edema (DME)</title><p>Safety and efficacy of pegaptanib were assessed in a randomized, sham-controlled, double-masked, Phase 2 trial enrolling 172 diabetic subjects with DME affecting the center of the fovea. Intravitreous injections were administered at baseline and every six weeks thereafter. At Week 36, 0.3 mg pegaptanib was significantly superior to sham injection, as measured by mean change in VA (+4.7 letters vs. -0.4 letters, <italic> P</italic> =0.04), proportions of patients gaining &#x02265;10 letters of VA (34% vs.10%; <italic> P</italic> =0.003), change in mean central retinal thickness (68&#x000b5;m decrease vs. 4 &#x000b5;m increase; <italic> P</italic> =0.02) and proportions of patients requiring subsequent photocoagulation treatment (25% vs. 48%, <italic> P</italic> =0.04).<xref ref-type="bibr" rid="ref15">15</xref>  In addition, a retrospective subgroup analysis revealed that pegaptanib treatment led to the regression of baseline retinal neovascularization in eight of 13 patients with proliferative diabetic retinopathy (PDR) whereas no such regression occurred in three sham-treated eyes or in four untreated fellow eyes.<xref ref-type="bibr" rid="ref16">16</xref>  Early results from a small, randomized, open-label study suggest that adding pegaptanib to panretinal photocoagulation conferred significant clinical benefit in patients with PDR.<xref ref-type="bibr" rid="ref17">17</xref></p></sec><sec><title>Macular edema secondary to central retinal vein occlusion (CRVO)</title><p>VEGF has been implicated in the pathophysiology of CRVO.<xref ref-type="bibr" rid="ref18">18</xref>  Accordingly, in a trial that enrolled subjects with CRVO of &#x0003c; 6 months duration,<xref ref-type="bibr" rid="ref19">19</xref>  98 subjects were randomized (1:1:1) to receive intravitreous pegaptanib (0.3 mg or 1 mg) or sham injections every six weeks and panretinal photocoagulation if needed. At Week 30, treatment with 0.3 mg pegaptanib was superior in terms of mean change in VA, proportions of patients losing &#x02265;15 letters from baseline, proportions with a final VA of &#x02265;35 letters and reduction in center point and central subfield thickness.<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref> </p></sec><sec><title>Investigational studies with pegaptanib</title><p>Encouraging findings have been reported in small case series investigating the use of pegaptanib for the treatment of neovascular glaucoma,<xref ref-type="bibr" rid="ref21">21</xref>  retinopathy of prematurity<xref ref-type="bibr" rid="ref22">22</xref>  and familial exudative vitreoretinopathy.<xref ref-type="bibr" rid="ref23">23</xref>  In addition, given its positive safety profile, now validated over three years in clinical trials and two and a half years of postmarketing experience, pegaptanib is being studied as a maintenance anti-VEGF inhibitor following induction with nonselective anti-VEGF agents such as ranibizumab or bevacizumab, which bind all VEGF isoforms<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref> and appear to be associated with an increased, albeit small, risk of stroke.<xref ref-type="bibr" rid="ref26">26</xref></p></sec></sec><sec sec-type=""><title>Conclusions</title><p>Pegaptanib is both safe and clinically effective for the treatment of all angiographic subtypes of neovascular AMD. Early, well-controlled trials further suggest that pegaptanib may provide therapeutic benefit for patients with DME, PDR and RVO. The roles that pegaptanib will ultimately play as part of the ophthalmologist&#x02032;s armamentarium remain to be established. The recent results with ranibizumab demonstrating the potential for significant vision gains in AMD<xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref>  have been impressive, but issues of safety remain to be definitively resolved;<xref ref-type="bibr" rid="ref26">26</xref> combinatorial regimens may ultimately prove to be most effective in balancing safety with efficacy.<xref ref-type="bibr" rid="ref24">24</xref>  Similarly, more established approaches, such as photodynamic therapy with verteporfin, may provide greater clinical benefit when combined with anti-VEGF therapy,<xref ref-type="bibr" rid="ref29">29</xref>  so that there is likely to be considerable space for empiricism in determining the best approach for a given patient. Nonetheless, the overall trend is highly positive, with the anti-VEGF agents affording many more options than were available only a few years ago. Such successes highlight the importance of VEGF in the pathogenesis of ocular vascular disorders and support the use of anti-VEGF agents as foundation therapy in patients with these conditions.</p></sec></body><back><ack><p>Editorial support, including contributing to the first draft of the manuscript, revising the paper based on author feedback and styling the paper for journal submission, was provided by Dr. Lauren Swenarchuk of Zola Associates and funded by Pfizer Inc.</p></ack><fn-group><fn><p>Source of Support: Pfizer Inc.</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>Vascular endothelial growth factor: Basic science and clinical progress</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><fpage>581</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">15294883</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senger</surname><given-names>DR</given-names></name><name><surname>Connolly</surname><given-names>DT</given-names></name><name><surname>Van de Water</surname><given-names>L</given-names></name><name><surname>Feder</surname><given-names>J</given-names></name><name><surname>Dvorak</surname><given-names>HF</given-names></name></person-group><article-title>Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor</article-title><source>Cancer Res</source><year>1990</year><volume>50</volume><fpage>1774</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2155059</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>EW</given-names></name><name><surname>Shima</surname><given-names>DT</given-names></name><name><surname>Calias</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Guyer</surname><given-names>DR</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name></person-group><article-title>Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease</article-title><source>Nat Rev Drug Discov</source><year>2006</year><volume>5</volume><fpage>123</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16518379</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Damico</surname><given-names>L</given-names></name><name><surname>Shams</surname><given-names>N</given-names></name><name><surname>Lowman</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name></person-group><article-title>Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>859</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17031284</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Goldbaum</surname><given-names>M</given-names></name></person-group><article-title>Macugen&#x000ae; (pegaptanib sodium) for the treatment of ocular vascular disease</article-title><source>Expert Rev Ophthalmol</source><comment>(In press)</comment></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Yamashiro</surname><given-names>K</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name><name><surname>Amano</surname><given-names>S</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Vegf164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>483</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12900522</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Yamashiro</surname><given-names>K</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Carrasquillo</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Vegf164 is pro-inflammatory in the diabetic retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>2155</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12714656</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>E</given-names></name><name><surname>Nishijima</surname><given-names>K</given-names></name><name><surname>Robinson</surname><given-names>GS</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Shima</surname><given-names>DT</given-names></name></person-group><article-title>VEGF has both direct and indirect neuroprotective effects in ischemic retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>4829</fpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gragoudas</surname><given-names>ES</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Feinsod</surname><given-names>M</given-names></name></person-group><collab>Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group</collab><article-title>Pegaptanib for neovascular age-related macular degeneration</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2805</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15625332</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><collab>VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group</collab><person-group person-group-type="author"><name><surname>Chakravarthy</surname><given-names>U</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Goldbaum</surname><given-names>M</given-names></name><name><surname>Guyer</surname><given-names>DR</given-names></name></person-group><article-title>Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>1508</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16828500</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>CR</given-names></name></person-group><collab>VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group.</collab><article-title>Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis</article-title><source>Retina</source><year>2005</year><volume>25</volume><fpage>815</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16205558</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><collab>VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group</collab><person-group person-group-type="author"><name><surname>D&#x02032;Amico</surname><given-names>DJ</given-names></name><name><surname>Masonson</surname><given-names>HN</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>992</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">16647134</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Suner</surname><given-names>IJ</given-names></name></person-group><article-title>Safety of pegaptanib sodium in age-related macular degeneration (AMD): 3-year results of the VISION trial</article-title><year>2006</year><conf-name>Poster presented at: The Annual Meeting of the American Academy of Ophthalmology</conf-name><conf-date>November 11-14, 2006</conf-date><conf-loc>Las Vegas, Nev</conf-loc><comment>Poster 715</comment></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="confproc"><person-group person-group-type="editor"><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><collab>the Macugen AMD Study Group.</collab><article-title>One-year systemic safety and pharmacokinetics of pegaptanib in patients with neovascular age-related macular degeneration (AMD).</article-title><year>2006</year><conf-name>Paper presented at: The Annual Meeting of the American Academy of Ophthalmology</conf-name><conf-date>November 11-14, 2006</conf-date><conf-loc>Las Vegas, Nev</conf-loc><comment>Poster 721</comment></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Altaweel</surname><given-names>M</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>D&#x02032;Amico</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>1747</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16154196</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Altaweel</surname><given-names>M</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Goldbaum</surname><given-names>M</given-names></name><etal/></person-group><article-title>Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16343627</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="confproc"><person-group person-group-type="editor"><name><surname>Gonzalez</surname><given-names>VH</given-names></name><name><surname>Vann</surname><given-names>VR</given-names></name><name><surname>Bandra</surname><given-names>RM</given-names></name></person-group><article-title>Selective VEGF Inhibition: Effectiveness in modifying the progression of proliferative diabetic retinopathy (PDR). </article-title><year>2006</year><conf-name>Poster presented at: The Annual Meeting of the American Academy of Ophthalmology</conf-name><conf-date>November 11-14, 2006</conf-date><conf-loc>Las Vegas, Nev</conf-loc><comment>Poster 309</comment></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>SR</given-names></name><name><surname>Zachary</surname><given-names>I</given-names></name><name><surname>Chakravarthy</surname><given-names>U</given-names></name><name><surname>Allen</surname><given-names>GJ</given-names></name><name><surname>Wisdom</surname><given-names>GB</given-names></name><name><surname>Cree</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>1644</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12470137</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="book"><comment>Data on file, (OSI) Eyetech, Inc: New York.</comment></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>JA</given-names><suffix>3 rd</suffix></name></person-group><collab>for the Pegaptanib in Retinal Central Vein Occlusion Study Group.</collab><article-title>Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion (CRVO)</article-title><source>Poster presented at: The Annual Meeting of the American Academy of Ophthalmology</source><year>2006</year><conf-date>November 11-14, 2006</conf-date><conf-loc>Las Vegas, Nev</conf-loc><comment>Poster 370</comment></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippopoulos</surname><given-names>T</given-names></name><name><surname>Ducharme</surname><given-names>JF</given-names></name><name><surname>Lowenstein</surname><given-names>JI</given-names></name><name><surname>Krzystolik</surname><given-names>MG</given-names></name></person-group><article-title>Antiangiogenic agents as an adjunctive treatment for complicated neovascular glaucoma</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>4476</fpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trese</surname><given-names>MT</given-names></name><name><surname>Capone</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Drenser</surname><given-names>K</given-names></name></person-group><article-title>Macugen in retinopathy of prematurity</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>2330</fpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Drenser</surname><given-names>KA</given-names></name></person-group><article-title>Macugen therapy for the treatment of familial exudative vitreoretinopathy</article-title><source>Paper presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology</source><conf-date>April 30-May 4, 2006</conf-date><conf-loc>Ft Lauderdale, Fla</conf-loc></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Sang</surname><given-names>DN</given-names></name></person-group><article-title>Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration</article-title><source>Ophthalmic Surg Lasers Imaging</source><year>2006</year><volume>37</volume><fpage>446</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17152537</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolentino</surname><given-names>MJ</given-names></name><name><surname>Misch</surname><given-names>DM</given-names></name><name><surname>Gerger</surname><given-names>AS</given-names></name></person-group><article-title>Avastin enhancement and Macugen maintenance therapy for exudative age-related macular degeneration</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>5912</fpage></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="webpage"><source>Genentech, Inc. Health-care provider letter</source><date-in-citation>[Last accessed on 2007 Jan 30</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.gene.com/gene/products/information/pdf/healthcare-provider-letter.pdf">http://www.gene.com/gene/products/information/pdf/healthcare-provider-letter.pdf</ext-link></comment></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Michels M; Soubrane</surname><given-names>G</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>RY</given-names></name><etal/></person-group><article-title>Ranibizumab versus verteporfin for neovascular age-related macular degeneration</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1432</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17021319</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Chung</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Ranibizumab for neovascular age-related macular degeneration</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1419</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17021318</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Ciulla</surname><given-names>TA</given-names></name><name><surname>Ferrone</surname><given-names>PJ</given-names></name><name><surname>Jumper</surname><given-names>JM</given-names></name><name><surname>Gentile</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study</article-title><source>Arch Ophthalmol</source><year>2006</year><volume>124</volume><fpage>1532</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17101999</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>Sequence and predicted secondary structure of pegaptanib <xref ref-type="bibr" rid="ref1">3</xref></p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-55-427-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Serious ocular adverse events, rates (% per injection)</p></caption><alt-text>Table 1</alt-text><graphic xlink:href="IndianJOphthalmol-55-427-g002"/></table-wrap></floats-group></article>